GGrantIndex
← Leaderboards

Michael W Lipscomb

Howard University

$4,141,610
Attributed
$4,141,610
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $849.7K · FY201525
$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,141,610 · 4

By mechanism

R35$1,779,721 · 1
SC1$1,494,445 · 1
SC2$441,194 · 1
R21$426,250 · 1

Top collaborators

No co-investigators on record.

Most similar at Howard University

Same institution · by research overlap

Others in their field

Top investigators on “T Cell Response

Research focus

T Cell ResponseDendritic CellsSignal TransductionImmunityImmune ResponseImmunotherapyCombatPublic Health RelevanceAntigen PresentationImmuneResponseInsightSuccessImmunoregulationTissuesDesignAutoreactive T CellCoupledIn VivoPathologyInnovationPlayGenesLaboratories

Grant awards (14)

Deciphering the immunoregulatory network governing antigen presenting myeloid cells$387,500
R35 · FY2025 · GM · contact PI
Deciphering the immunoregulatory network governing antigen presenting myeloid cells$387,500
R35 · FY2024 · GM · contact PI
Deciphering the immunoregulatory network governing antigen presenting myeloid cells$387,500
R35 · FY2023 · GM · contact PI
Delineating the function of MHC class III genes in antigen presenting myeloid cell contribution to autoimmunity$232,500
R21 · FY2023 · AI · contact PI
Deciphering the immunoregulatory network governing antigen presenting myeloid cells$229,721
R35 · FY2023 · GM · contact PI
Deciphering the immunoregulatory network governing antigen presenting myeloid cells$387,500
R35 · FY2022 · GM · contact PI
Delineating the function of MHC class III genes in antigen presenting myeloid cell contribution to autoimmunity$193,750
R21 · FY2022 · AI · contact PI
Development of tolerogenic dendritic cell-based immunotherapies and restorative insulin approaches to alleviate type 1 diabetes$377,500
SC1 · FY2021 · GM · contact PI
Development of tolerogenic dendritic cell-based immunotherapies and restorative insulin approaches to alleviate type 1 diabetes$377,500
SC1 · FY2020 · GM · contact PI
Development of tolerogenic dendritic cell-based immunotherapies and restorative insulin approaches to alleviate type 1 diabetes$377,500
SC1 · FY2019 · GM · contact PI
Development of tolerogenic dendritic cell-based immunotherapies and restorative insulin approaches to alleviate type 1 diabetes$361,945
SC1 · FY2018 · GM · contact PI
Crosstalk and the cytoskeleton in dendritic cell antigen presentation$151,000
SC2 · FY2017 · GM · contact PI
Crosstalk and the cytoskeleton in dendritic cell antigen presentation$151,000
SC2 · FY2016 · GM · contact PI
Crosstalk and the cytoskeleton in dendritic cell antigen presentation$139,194
SC2 · FY2015 · GM · contact PI